During primary neurogenesis in Xenopus, a cascade of helix-loop-helix (HLH) transcription factors regulates neuronal determination and differentiation. While XNeuroD functions at a late step in this cascade to regulate neuronal differentiation, the factors that carry out terminal differentiation are still unknown. We have isolated a new Xenopus member of the Ebf/Olf-1 family of HLH transcription factors, Xebf3, and provide evidence that, during primary neurogenesis, it regulates neuronal differentiation downstream of XNeuroD. In developing Xenopus embryos, Xebf3 is turned on in the three stripes of primary neurons at stage 15.5, after XNeuroD. In vitro, XEBF3 binds the EBF/OLF-1 binding site and functions as a transcriptional activator. When overexpressed, Xebf3 is able to induce ectopic neurons at neural plate stages and directly convert ectodermal cells into neurons in animal cap explants. Expression of Xebf3 can be activated by XNeuroD both in whole embryos and in animal caps, indicating that this new HLH factor might be regulated by XNeuroD. Furthermore, in animal caps, XNeuroD can activate Xebf3 in the absence of protein synthesis, suggesting that, in vitro, this regulation is direct. Similar to XNeuroD, but unlike Xebf2/Xcoe2, Xebf3 expression and function are insensitive to Delta/Notch-mediated lateral inhibition. In summary, we conclude that Xebf3 functions downstream of XNeuroD and is a regulator of neuronal differentiation in Xenopus.
INTRODUCTION
In the past few years, as the molecular mechanisms underlying neurogenesis have become clearer, it has been shown that cascades of transcription factors are involved both in neuronal determination and differentiation. Basic helix-loop-helix (bHLH) proteins play an important role in these regulatory cascades (Kageyama and Nakanishi, 1997; Lee, 1997) . In Drosophila, the bHLH transcription factors encoded by the achaete-scute complex (AS-C) and atonal genes provide cells with the potential to adopt a neural fate, and thus they have been called "proneural genes" (Alonso and Cabrera, 1988; Campuzano and Modolell, 1992; Jarman et al., 1993 Jarman et al., -1995 Gupta and Rodrigues, 1997) . In vertebrates, several homologs of AS-C or atonal have now been identified, such as Mash1, ngn/ Math4, and Math1 in mammals and Xash1, Xash3, Xath1, Xath5, and X-ngnr-1 in Xenopus laevis (Ferreiro et al., 1992; Zimmerman et al., 1993; Ma et al., 1996; Sommer et al., 1996; Kanekar et al., 1997; Kim et al., 1997; Fode et al., 1998; Ben-Arie et al., 2000) . Evidence that these bHLH genes promote neurogenesis is provided by overexpression studies in Xenopus and by targeted gene disruption in mouse.
During primary neurogenesis in Xenopus laevis, expression of the bHLH gene neurogenin-related-1 (X-ngnr-1), a vertebrate neuronal determination gene, defines three territories of primary neurogenesis in the developing neural plate . Expression of X-ngnr-1 precedes expression of another bHLH factor, XNeuroD, a regulator of neuronal differentiation (Lee et al., 1995; Ma et al., 1996) . X-ngnr-1 and XNeuroD function in a unidirectional cascade to regulate primary neurogenesis. Overexpression of X-ngnr-1 induces formation of ectopic neurons in nonneural ectoderm and induces ectopic expression of XNeuroD . Similarly, overexpression of XNeuroD is also able to promote the formation of ectopic neurons (Lee et al., 1995) . These findings suggest that X-ngnr-1 and XNeuroD function to regulate successive stages of neuronal differentiation in the developing neural plate. However, the factors that function downstream of XNeuroD to regulate neuronal differentiation have not yet been defined.
Neurogenesis in both invertebrates and vertebrates is negatively regulated through the mechanism of lateral inhibition. A cell expressing the ligand Delta is able to activate the receptor Notch in neighboring cells, inhibiting them from becoming neuronal precursors (ArtavanisTsakonas et al., 1995; Lewis, 1996) . This cell-cell interaction antagonizes the expression or activity of the proneural genes through the activation of negative regulatory bHLH factors such as Enhancer of split (E(Spl)) in Drosophila, or HES genes in vertebrates (Sasai et al., 1992; Barolo and Levine, 1997; Bray, 1997; Wettstein et al., 1997) . During primary neurogenesis in Xenopus, activation of the Notch receptor suppresses neuronal differentiation, in part by antagonizing X-ngnr-1 activity (Chitnis et al., 1995; Chitnis and Kintner, 1996; Ma et al., 1996) . In contrast, the activity of XNeuroD is relatively insensitive to inhibition by Notch (Chitnis and Kintner, 1996) .
It has been recently demonstrated that another gene family, the Ebf/Olf family, is involved in neurogenesis, both in invertebrates and vertebrates (Davis and Reed, 1996; Garel et al., 1999) . The EBF transcription factors contain a HLH dimerization domain and a novel zinc finger DNA binding domain, while they lack the basic region that mediates the DNA interactions in the bHLH factors. In vitro, these proteins bind an imperfect palindromic DNA consensus sequence both as homo-and heterodimers (Hagman et al., 1991; Travis et al., 1993; Hagman et al., 1995) . Ebf (Early B-cell Factor)/Olf-1 (olfactory-neuronal transcription factor) was independently cloned in mouse and rat . Two other mouse genes were then identified, Ebf2 (O/E3, Mmot1) and Ebf3 (O/E2), along with Xenopus and zebrafish Ebf2 homologs, Xcoe2 and Zcoe2 (Garel et al., 1997; Malgaretti et al., 1997; Wang et al., 1997; Bally-Cuif et al., 1998; Dubois et al., 1998) . In addition, members of this family have been cloned in invertebrates: collier, a regulator of anterior head patterning in Drosophila, and unc3(CeO/E) in C. elegans (Crozatier et al., 1996 Prasad et al., 1998; Vervoort et al., 1999) .
In the murine neural tube, the Ebf genes are expressed in the same regions, but Ebf2 is turned on in young postmitotic neurons of the subventricular zone, while Ebf1 and Ebf3 are expressed in differentiating neurons of the mantle layer (Garel et al., 1997; Malgaretti et al., 1997 ; O.P., L.C., and G.G.C., unpublished results). In Xenopus, Xebf2/Xcoe2 expression is detected in the three stripes of primary neurons and it is turned on after X-ngnr-1 and before XNeuroD . Overexpression of Xebf2/Xcoe2 gives rise to a nonuniform pattern of ectopic neurons both in the neural plate and in the presumptive epidermis . Xebf2/Xcoe2 overexpression induces ectopic neurons positive for X-ngnr-1, XDelta-1 (XDl-1), and XNeuroD. During normal development, X-ngnr-1 is expressed earlier than Xebf2/Xcoe2, thus it has been proposed that, in Xebf2/Xcoe2-overexpressing embryos, X-ngnr-1 ectopic expression results from a positive feedback mechanism .
Xebf2/Xcoe2 functions at an early step in the genetic cascade regulating primary neurogenesis, acting after X-ngnr-1 but before XNeuroD . However, it is still unclear which factors regulate neurogenesis downstream of XNeuroD. We describe here a new member of the Ebf/Olf-1 family, Xebf3, that we propose functions as a regulator of neuronal differentiation in Xenopus. In the developing embryo, Xebf3 expression follows that of XNeuroD, and can be activated by overexpression of XNeuroD. In addition, Xebf3 can regulate neuronal differentiation since overexpression of Xebf3 promotes ectopic neurogenesis both in whole embryos and in animal cap explants. Similarly to XNeuroD, but unlike Xebf2/Xcoe2, Xebf3 function appears to be insensitive to lateral inhibition. Our results show that Xebf3 is a new regulator of primary neurogenesis in Xenopus, acting downstream of XNeuroD during neuronal differentiation.
MATERIALS AND METHODS

Cloning of Xebf3
The Xebf3 cDNA clone was obtained by screening a stage 28 -30 (tailbud tadpole) Xenopus head cDNA library made by Harland (1991). We used a mouse Ebf2 cDNA probe including the HLH domain and performed hybridization with low stringency conditions (0.5 M Na 2 HPO 4 , 1 mM EDTA, 7% SDS, pH 7.2, at 60°C, washes with 40 mM Na 2 HPO 4 , 1% SDS, pH 7.2, at RT). For positive clones, this was followed by an in vivo excision of the pBlueScript phagemid from the ZAP II vector and by automated sequencing (Primm Labs Sequencing Facility). Sequence analysis and contig assembly were performed by using the MacVector program (Oxford Molecular Group) and the Sequencher program (Gene Code Corp.), respectively. The nucleotide sequence of the largest cDNA clone (2.1 kb), which contained the complete open reading frame, was deposited into the GenBank database with accession number AF040994. With the same screening we also obtained the Xenopus Ebf2 homolog, Xebf2, independently cloned as Xcoe2 .
In Vitro Assays
Electrophoretic mobility shift assay.
In vitro transcription and translation were performed by using the TnT Coupled Reticulocyte Lysate Systems (Promega) according to the manufacturer's recommendation. The efficiency of in vitro translation was assayed by running parallel translation reaction performed in the presence of [
35 S]methionine (Amersham). The double-stranded synthetic DNA fragment carrying the binding site for the EBF1 protein (5Ј-ACCCATGCTCTGGTCCCCAAGGAGCCTGTC-3Ј) (Kudrycki et al., 1993) and a control DNA fragment where the binding site had been mutated (5Ј-ACCCATGCTCTGGTCAGCAAGGAGC-CTGTC-3Ј) were end-labeled with [␣- 32 P]dATP (Amersham) using 20 units of T4 polynucleotide kinase (Ambion). In vitro DNA binding and electrophoretic mobility shift assay were performed as described (Malgaretti et al., 1997) . In each binding reaction (20 l), we employed 0.15 pmol of labeled doubled-stranded DNA (about 40,000 cpm); 10 l were then applied to a nondenaturating 6% polyacrylamide gel.
Luciferase activity assay. NIH3T3 cells were maintained in Dulbecco's-modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Euro Clone), 2 mM L-glutamine (Euro Clone), 100 IU/ml penicillin, and 100 g/ml streptomycin. Calcium phosphate-mediated transfection (Di Nocera and Dawid, 1983) was performed in a 60-mm Petri dish with 5 g of expression construct, 10 g of reporter plasmid, and 300 ng of pRL-TK (Promega) as an internal control. Cells were harvested 60 h after transfection, lysed, and assayed for luciferase activity (DualLuciferase Reporter Assay System Kit, Promega). All luciferase assays were performed in triplicate. The pT81-mb1 reporter vector was composed of a 200-bp DNA fragment of the mb1 promoter region obtained by PCR amplification with primers mb1-F: 5Ј-CAGGGATCCATGGTGATGAA-3Ј and mb1-R: 5Ј-CTCCG-CCTCACTTCCTGT-3Ј, using mouse genomic DNA as template. PCR conditions were 3 min at 94°C, 2 min at 80°C in which Pfu polymerase was added (hot start), followed by 30 cycles of 1 min at 94°C, 1 min at 56°C, 1 min at 72°C, with a final elongation step of 10 min at 72°C. The amplified DNA containing one EBF/OLF-1 binding site, 5Ј-CAAGGGAAT-3Ј (Hagman et al., 1991) , was cloned into the SmaI site of the pT81 luciferase reporter vector (Zappavigna et al., 1991) , and sequenced (Biostrands).
Microinjection of RNA
The Xebf3 and Xebf2 coding sequences were subcloned into the StuI site of the expression vector CS2ϩ (Turner and Rupp, 1995) and were tested by in vitro translation (TnT Coupled Reticulocyte Lysate System; Promega). The CS2ϩMT-hGR-XNeuroD construct was generated by amplifying the ligand binding domain of the human glucocorticoid receptor (hGR) from the plasmid pSP64T-MyoDGR (Kolm and Sive, 1995) , using the forward primer 5Ј-CGCGGATCCGCCATGGCCTCTGAAAATCCTGGTAAC-3Ј and the reverse primer 5Ј-GCGGCGGGGCATCTAGATTACTTT-TGATG-3Ј. The PCR product was digested with BamHI and XbaI and cloned into CS2ϩMT. The XNeuroD coding sequence was cut from the plasmid CS2ϩMT-XNeuroD with XbaI and subcloned in frame into the XbaI site of the CS2ϩMT-hGR plasmid. The final construct was tested by in vitro translation and in vivo for the ability to generate hormone-dependent ectopic neurons at neural plate stages. Capped mRNA was transcribed in vitro by using the linearized plasmids CS2ϩXebf3, CS2ϩXebf2, CS2ϩMT-XNeuroD (Lee et al., 1995) , CS2ϩNotch-ICD (Chitnis et al., 1995) , CS2ϩX-Delta1 stu (Chitnis et al., 1996) , CS2ϩMT-hGR-XNeuroD, and CS2ϩnuclear ␤galactosi-dase (n␤gal; Chitnis et al., 1995) as DNA templates (Message Machine Kit; Ambion).
For two-cell stage experiments, we injected capped mRNA in a volume of 4 nl into one of the two blastomeres of albino embryos, using the uninjected side as a control. We used the following RNA amounts: Xebf3 (0.5 ng), Xebf2 (0.5 ng), XNeuroD (0.5 ng), Notch-ICD (0.1 ng), and n␤gal (0.015 ng). The injected embryos were cultured and staged according to Nieuwkoop and Faber (1994) , fixed in MEMFA (Harland, 1991) for 1 h at room temperature, and then stored in methanol. X-gal staining was performed on albino embryos coinjected with n␤gal RNA according to Turner and Weintraub (1994) .
Isolation of Caps, RNA Extraction, and RT-PCR
To isolate animal caps, we injected 4 nl of capped mRNA (Xebf3 0.5 ng, Xebf2 0.5 ng, XNeuroD 0.5 ng, and hGR-XNeuroD 0.8 ng) into the animal pole of one-cell stage pigmented embryos. Animal caps were cut from injected embryos at stage 8 in 1ϫ MMR by using the Gastromaster Microsurgery machine (Xenotek Engineering); the caps were cultured in 1ϫ MMR until control embryos were at neural plate stage and then harvested to extract RNA. For the hormone-inducible XNeuroD experiments, we treated the caps with 10 uM dexamethasone (Sigma) and 10 uM cycloheximide (Sigma) as previously described by Gammill and Sive (1997) , except that the caps were cultured in the presence of the protein synthesis inhibitor for 3 h instead of 5, to increase the viability of the caps. To test translational inhibition, we incubated the caps in 1ϫ MMR containing 1 mCi/ml of [ 35 S]methionine, according to Gammill and Sive (1997) . We observed a translational inhibition Ͼ90% in the caps incubated in the presence of cycloheximide (data not shown).
Total RNA was extracted from harvested animal caps using the Trizol Reagent (Gibco BRL) and then used to perform a reverse transcription reaction with oligo-dT 12-18 primers. We used the following primers, Xebf3 (F: 5Ј-CCTACAAGTCAAAGCAGTTCT-3Ј, R:
5Ј-CAACC TTCCCATCAACCA-3Ј), Muscle actin (F: 5Ј-GCT-GACAGAATGCAGAAG-3Ј, R: 5Ј-TTGCTTGGAGGAGTGTGT-3Ј), and EF1␣ (F: 5Ј-CAGATTGGTGCTGGATATGC-3Ј, R: 5Ј-ACTGCCTTGATGACTCCTAG-3Ј) with these PCR conditions: 3Ј at 94°C, 28 cycles of 1 min at 94°C, 45 s at 56°C, 1 min at 72°C, and a final elongation step of 5Ј at 72°C, except for EF1␣ (19 cycles instead of 28 to stay in the linear range). The RT-PCR were run on an agarose gel, normalized to EF1␣, and acquired with the Multi-Analyst program.
In Situ Hybridization and Antibody Staining
Antisense RNA probes were generated by in vitro transcription (T3-T7 MaxiScript Kit; Ambion), and labeled with digoxigenin-11-UTP (Boehringer Mannheim) for Xebf3 and Xebf2, XHox11L2, and XHoxB9 . The Xebf probes correspond to the full-length sequences and show 85% identity at the nucleotide level. The pBlueScript-XNF-M plasmid was generated by using a forward primer (5Ј-CCATCCAGCAGCT-GGACAAT-3Ј) and a reverse primer (5Ј-CTGTCTCCTCATC-CTCTCCTT-3Ј) to amplify the XNF-M coding region from Xenopus total cDNA (stage 40). The PCR product (1 kb) was cloned into the EcoRV site of pBlueScript SK II (Stratagene).
Whole-mount in situ hybridization was performed on albino Xenopus embryos as described by Harland (1991) , except that BM purple (Boehringer Mannheim) was used as the substrate for the alkaline phosphatase (Kanekar et al., 1997) . After in situ hybridization, some embryos were cleared using a 2:1 mixture of benzyl benzoate/benzyl alcohol. Paraffin sections (20 m) were cut from stained embryos.
FIG. 1.
Protein sequence comparison of Xenopus and mouse EBF family of transcription factors. (A) Amino acid sequence alignment of XEBF3, XEBF2, and the three mouse EBF proteins, using the MacVector program. Identical residues are boxed and the DNA binding domain is indicated by light gray background. In this highly conserved region (Ͼ95% identity), which includes a zinc-finger motif (amino acids 151-177), the boxed columns indicate residues important for EBF1 DNA binding and the black dots show the amino acids essential for this binding (Hagman et al., 1995) . These residues are identical in all five EBF proteins. The HLH dimerization domain also shows a very high level of homology (Ͼ94% identity) and is indicated by dark gray background. (B) Phylogenetic analysis of the EBF factors. The tree was created by comparing the protein sequences with the ClustalW method by using the MacVector program.
Immunostaining was performed by using an anti-N-CAM monoclonal antibody (6F11) hybridoma supernatant diluted 1:10, as previously described (Turner and Weintraub, 1994) . The primary antibody was detected with a horseradish peroxidase-conjugated sheep anti-mouse antibody (Jackson Laboratories) diluted 1:500, followed by reaction with diaminobenzidine (DAB). (m, i, l) . At this stage, the neural plate is invaginating to form the neural tube. In tailbud stage embryos (C-E), Xebf3 was expressed in some branchial arches, olfactory placode, neural tube (mesencephalon, rhombencephalon, and spinal cord), retina, and otic vesicle. Embryos in (C-E) were cleared using a 2:1 mixture of benzyl benzoate/benzyl alcohol. Abbreviations: ba, branchial arches; ms, mesencephalon; op, olfactory placode; ov, otic vesicle; r, retina; rh, rhombencephalon; sc, spinal cord.
FIG. 2. Xebf3 is expressed in the developing
RESULTS
Identification and Expression of Xebf3 in the Xenopus Embryo
To identify members of the Ebf gene family in Xenopus laevis, we used a murine Ebf2 cDNA probe spanning the whole HLH domain to screen a stage 28 -30 Xenopus head cDNA library at low stringency. Several positive clones were obtained, including a 2.1-kb clone with a complete open reading frame encoding a new Xenopus member of the EBF/OLF-1 family. This gene, which we named Xebf3, encodes a protein of 598 amino acid residues (Fig. 1A) . On the basis of sequence alignment, this HLH transcription factor is most closely related to mouse Ebf3 (Fig. 1B) . The mouse EBF3 and the frog protein show 95% identity in the overall sequence, 97% in the DNA binding domain (amino acids 51-252), 95% in the HLH domain (amino acids 368 -430), and 90% identity in the C-terminal transactivation domain (amino acids 431-596).
To define a role for Xebf3 in the developing embryo, we performed an analysis of Xebf3 expression by whole-mount in situ hybridization, showing that Xebf3 is mainly restricted to the nervous system. Xebf3 expression is first detected at stage 13.5 in the trigeminal placodes (data not shown), and, at stage 15.5, Xebf3 starts to be expressed in the neural plate within the three stripes of primary neurons (Figs. 2A and 2B) . At neural plate stages, the pattern of Xebf3 expression is similar to that of Xebf2/Xcoe2, which precedes Xebf3 expression by several hours . At stage 20 (data not shown), Xebf3 continues to be expressed in the neural tube, olfactory placodes, and is strongly detected in the cranial neural crest cells. At the tailbud stage (Fig. 2C ), Xebf3 is expressed in the neural tube and head, in particular in the olfactory placodes and in the migrating neural crest cells. After their migration, the cranial neural crest cells contribute to the branchial arches and their derivatives, mainly to the skeleton of the head and the cranial ganglia. At stage 28 (Fig. 2D ), Xebf3 is detected in the first three branchial arches, in the olfactory placodes, in the otic vesicle, and in the neural tube from the midbrain through the spinal cord. Transverse sections of stained embryos at this stage reveal that Xebf3 is restricted to the dorsal mantle layer of the neural tube, similar to the distribution of Xebf2/Xcoe2 (data not shown; Dubois et al., 1998) . Around stage 32 (Fig. 2E ), Xebf3 maintains this expression pattern but is also detected in the retina. At late stages of development, the pattern of Xebf3 expression is very similar to that of Xebf2/Xcoe2; however, Xebf3 is expressed in the developing retina while Xebf2 is not, and these two genes show different patterns of expression in the branchial arches. For probes, we used full-length clones of Xebf2 and Xebf3, which are 85% identical. The different onsets of expression of the Xebf genes and their similar, but not identical, expression patterns during late stages of development indicate that the two riboprobes do not crossreact. At multiple stages of development, the Xebf3 expression pattern partially overlaps that of XNeuroD (Lee et al., 1995) , in particular in the neural tube (midbrain, hindbrain, and spinal cord), in some derivatives of the neural crest, olfactory placodes, and retina. However, some regions of the embryo express only XNeuroD and not Xebf3 (pineal gland), while other regions express only Xebf3 and not XNeuroD (some branchial arches). In addition, during late stages of development, Xebf3 expression is maintained while XNeuroD is only transiently expressed in some postmitotic neurons (Lee et al., 1995;  and data not shown).
XEBF3 Shares the Biochemical Properties of the Other EBF Proteins
To determine whether XEBF2/XCOE2 and XEBF3 share the same biochemical functions, we tested their DNA binding specificity and transactivation activity and we compared them to those observed for the mouse EBF proteins, which have been biochemically well characterized Hagman et al., 1995; Wang et al., 1997) . We synthesized the mouse and the Xenopus proteins by in vitro translation and performed a gel mobility shift assay (EMSA), using labeled double-stranded oligonucleotides representing the imperfect palindromic EBF-binding site, 5Ј-ACCCATGCTCTGGTCCCCAAGGAGCCTGTC-3Ј (Kudrycky et al., 1993) . Our results suggest that the Xenopus proteins are able to bind the wild-type palindromic sequence as dimers (Fig. 3A) since mouse EBF1 is known to bind as a dimer (Hagman et al., 1995) and XEBF3 is structurally similar to, and has the same MW as, EBF1. In EMSA assays, XEBF3 and EBF1 give rise to gel shift bands of identical sizes. This binding is specific since the proteins no longer bind to a mutated EBF target site (Fig. 3B) . In the gel, we observed a different intensity of the shifted bands due to a different efficiency of in vitro translation of the EBF proteins (data not shown).
Since the EBF transcription factors are highly conserved, we also tested their ability to activate transcription of a target gene in vitro. We cotransfected NIH3T3 cells with an EBF/XEBF expression vector and a reporter plasmid containing the luciferase gene under the control of a TK basal promoter and 200 bp of the mb1 distal promoter, which contains the imperfect EBF-binding site 5Ј-CAAGGGAAT-3Ј (Hagman et al., 1991; Travis et al., 1993) . We obtained a high basal value when the reporter plasmid was transfected alone, due to a low endogenous expression of Ebf1 in the NIH3T3 cells (data not shown). However, we observed a significant activation of the reporter gene with both XEBF3 and XEBF2 as well as with mouse EBF2, used as a positive control (Fig. 3C) . Although the increases observed with the XEBF proteins were always significant, we noticed that they were consistently weaker than with mouse EBF2, probably because these Xenopus transcription factors are less efficient in a mouse assay system. In conclusion, our results demonstrate that, in vitro, both XEBF3 and XEBF2/ XCOE2 show similar DNA binding and transactivation activity.
Ectopic Expression of Xebf3 Converts Ectodermal Cells into Neurons
In the molecular cascade regulating primary neurogenesis in Xenopus, X-ngnr-1 is the first HLH factor to be turned on and its expression defines the three stripes of primary neurons . Temporally, Xebf2/Xcoe2 follows X-ngnr-1 and precedes XNeuroD activation . It has been demonstrated that Xebf2/Xcoe2 overexpression promotes ectopic scattered neurogenesis in both the neural plate and dorsal epidermis Figs. 4E and 4F : N-tubulin, 74% of embryos, n ϭ 38; Neurofilament-M (XNF-M), 81% of embryos, n ϭ 18). To test whether overexpression of Xebf3 is able to induce ectopic neurons, we injected Xebf3-capped mRNA into one cell of two-cell stage embryos, using the uninjected side as an internal control, and we cultured them until neural plate stage. We performed in situ hybridization experiments and counted the percentage of embryos showing ectopic expression of the neural-specific marker N-tubulin. We observed a dose-dependent generation of ectopic neurons, mainly restricted to the posterior portion of the presumptive epidermis and to the lateral stripe (69%, n ϭ 47; Fig. 4C , and data not shown). This result was confirmed by using another neural-specific marker, neurofilament-M, which starts to be expressed in the developing embryo at stage 19 (XNF-M, 89%, n ϭ 19; Fig. 4D , and data not shown). In both cases, the ectopically activated neural markers were expressed in a scattered cell pattern. Interestingly, we observed that XNF-M was much more robustly activated than N-tubulin and it was strongly present throughout the injected side of the embryo before its normal onset of expression. In mouse, the neurofilament-M promoter contains a presumptive EBFbinding site (A.B. and G.G.C., unpublished) , therefore this strong ectopic expression in Xebf3-injected embryos might reflect a direct activation of neurofilament-M by Xebf3. Xebf3-injected embryos stained at stage 28 with an anti-N-CAM antibody showed that some of these epidermal cells differentiated into process-bearing neurons (Fig. 4G, arrow-FIG. 3 . XEBF3 binds the EBF/OLF-1 binding site and can activate transcription in vitro. The DNA binding and transactivation activities of XEBF3 and XEBF2/XCOE2 were compared to the mouse EBF proteins. (A, B) Gel mobility shift assay showing specific affinity of the EBF/XEBF factors for the EBF/OLF-1 palindromic binding site. Blank, no lysate; RRL, rabbit reticulocyte lysate only; other lanes, in vitro-synthesized, unlabeled EBF/XEBF proteins. All of the reactions were incubated with [␣-32 P] end-labeled double-stranded oligonucleotide containing either a wild-type or mutated EBF/ OLF-1 binding site derived from the OMP (Olfactory Marker Protein) promoter and then run on a nondenaturating polyacrylamide gel. A shifted band was observed after the incubation of all of the EBF/XEBF proteins with the wild-type binding site (A), but not with a mutated site (B). (b) Indicates the shifted bands and (f) the free probe. (C) Luciferase assay revealing the different levels of transactivation activity of the EBF family members. Luciferase activity was measured in luciferase units and was assayed from lysates of NIH3T3 cells. The cells were transfected with 5 g of either the pcDNA3 expression plasmid or pcDNA3 containing coding sequence for the following EBF factors: mouse EBF2, XEBF2, XEBF3. A total of 10 g of the luciferase reporter plasmid pT81 either containing (mb1) or lacking (pT81) the mb1 promoter sequence was cotransfected into the cells to monitor transactivation activity of the expressed proteins. In all of the samples, 300 ng of pRL-TK was transfected as an internal control. The graph is labeled so that, for each bar, the expression plasmid is listed first and the reporter plasmid is listed last (e.g., EBF2-mb1). Values indicate the mean of the results from three independent experiments and all of the columns indicated by an asterisk (*) are statistically different from control luciferase values (*, P Ͻ 0.0002; **, P Ͻ 0.001 by Student's t-test).
heads). Analysis of Xebf3-injected embryos using markers for specific neuronal subtypes indicated that Xebf3 induced ectopic expression of XHox11L2 (87%, n ϭ 21; Fig. 4H ), a cranial sensory ganglia and Rohon-Beard neurons marker (Patterson and Krieg, 1999 ), but did not induce the expression of XHoxB9 (Saha et al., 1997) and Xlim3 (Taira et al., 1993) , which identify primary motor neurons starting at early tailbud stage (data not shown). Similarly, we did not observe ectopic activation of the interneuron marker Pax2 (Heller and Brandli, 1997 , and data not shown). These results suggest that Xebf3 promotes differentiation of specific neuronal subtypes which show the characteristics of sensory neurons.
To confirm that Xebf3 overexpression is sufficient to convert nonneuronal cells (epidermis) into neurons, we injected Xebf3 mRNA into one-cell stage embryos, isolated animal caps at midblastula stage (stage 8), and cultured them until control embryos were at neural plate stage. In both the Xebf3-and Xebf2/Xcoe2-injected animal caps, we observed activation of the neural-specific markers N-CAM (Kintner and Melton, 1987) , N-tubulin, and XNF-M by RT-PCR (Fig. 4I) . XNeuroD-injected caps were used as a positive control. There was no evidence for activation of the mesodermal marker muscle actin, demonstrating that the neuralization of these caps was direct. These results show that Xebf3 is able to induce neurogenesis and to convert ectodermal cells into neurons both in vivo and in animal caps.
In Vivo, XNeuroD Activates Expression of Xebf3 but Not of Xebf2/Xcoe2
It has been shown that X-ngnr-1 strongly activates Xebf2/ Xcoe2, which turns on XNeuroD and also maintains X-ngnr-1 expression through a positive feedback mechanism (Dubois et al., 1998, and Figs. 5F and 5G: X-ngnr-1, 72% , n ϭ 23; XNeuroD, 68%, n ϭ 19). These results suggest that Xebf2/Xcoe2 is involved in primary neurogenesis and promotes neuronal differentiation by activating XNeuroD. Because XNeuroD is turned on before Xebf3 and after Xebf2/Xcoe2, we analyzed the effects of the ectopic XNeuroD expression on both Xebf3 and Xebf2/Xcoe2 expression. XNeuroD mRNA was injected into embryos at the two-cell stage, and the embryos were cultured and then collected at neural plate stage. Overexpression of XNeuroD caused ectopic expression of Xebf3 (78%, n ϭ 29), while Xebf2/ Xcoe2 was not activated (100%, n ϭ 22; Figs. 5A and 5B). This result and the fact that Xebf3 expression temporally follows and partially overlaps that of XNeuroD suggest that Xebf3 could be a transcriptional target of XNeuroD. Overexpression of Xebf2/Xcoe2 promoted the activation of XNeuroD (68%, n ϭ 19; Figs. 5G and 5M) and also of Xebf3 (76%, n ϭ 23; Figs. 5H and 5M), but not vice versa (Figs. 5D, 5E and 5L; XNeuroD, 91%, n ϭ 31; Xebf2/Xcoe2, 84%, n ϭ 38).
To confirm that overexpression of XNeuroD causes activation of Xebf3, we performed animal cap experiments. In these assays, we used RNA extracted from uninjected total embryos harvested at stage 18 as a positive control. We observed a strong ectopic activation of Xebf3 and an interesting weak activation of Xebf2/Xcoe2 in caps isolated from XNeuroD-injected embryos compared to ␤gal-injected control caps (Fig. 5I) . Our in vivo data also suggested that Xebf2 could activate expression of XNeuroD and Xebf3, while Xebf3 could not activate XNeuroD or Xebf2. To confirm these regulatory relationships, we performed animal cap experiments and observed that Xebf3 overexpression did not promote ectopic activation of Xebf2 or XNeuroD (Fig.  5L) , while caps isolated from Xebf2-injected embryos showed ectopic expression of both Xebf3 and XNeuroD (Fig.  5M) , similar to what is observed in vivo. In summary, our gain-of-function results and the sequential onset of expres- 1 and 3) . Muscle actin was used as a mesodermal marker, and EF1␣ was used to normalize the samples. sion of these HLH factors demonstrate that Xebf3 functions downstream of XNeuroD in the molecular cascade that regulates neuronal differentiation in Xenopus.
Xebf3 Expression Can Be Directly Activated by hGR-XNeuroD in Animal Cap Explants
Our results show that Xebf3 is turned on in the neural plate after XNeuroD and that overexpression of XNeuroD activates ectopic Xebf3, both in vivo and in animal cap explants. To determine whether Xebf3 is a direct target of XNeuroD in vitro, we constructed a hormone-inducible XNeuroD fusion protein by adding the ligand-binding domain of the human glucocorticoid receptor (hGR) to the XNeuroD coding region (hGR-XNeuroD). To test the function of hGR-XNeuroD, we injected capped mRNA into one blastomere of two-cell stage embryos and assayed for the formation of ectopic N-tubulin positive cells by wholemount in situ hybridization. We observed extensive ectopic expression of N-tubulin in the injected side in embryos treated with dexamethasone, while no ectopic neurons were detected in the injected embryos incubated without the hormone (Hutcheson and Vetter, 2001 ). If Xebf3 is a direct target of XNeuroD in vitro, it should be activated by hGR-XNeuroD in the absence of protein synthesis. To test this, we injected hGR-XNeuroD RNA into one-cell stage pigmented embryos and cut animal caps at stage 8. The caps were then pretreated for 30 min with cycloheximide, an inhibitor of protein synthesis, then cultured with or without dexamethasone and cycloheximide for 2.5 h (Gammill and Sive, 1997) . To verify the block of protein synthesis, some of the caps were assayed for the incorporation of [ 35 S]methionine. We observed greater than 90% translational inhibition in the caps incubated in the presence of cycloheximide (data not shown). The caps were then harvested to extract total RNA and the expression of Xebf3 was assayed by RT-PCR. We observed a significant activation of Xebf3 expression when hGR-XNeuroD was activated by dexamethasone both in the presence and absence of protein synthesis (Fig. 6, lanes 1 and 2) , while no activation of Xebf3 was detected without the hormone (Fig. 6, lanes 3 and 4) . This suggests that the transcriptional regulation of Xebf3 by hGR-XNeuroD is direct. To further ensure that we had effectively inhibited protein synthesis with CHX, we assayed for activation of XNF-M expression by hGRXNeuroD. We found that XNF-M was activated only in the presence but not in the absence of protein synthesis (Fig. 6 , lanes 1 and 2) demonstrating that, in contrast to Xebf3, XNF-M is only indirectly regulated by XNeuroD. We normalized the level of Xebf3 and XNF-M expression by testing the ubiquitous EF1␣ transcript. To confirm these results and ensure that we were in the linear range of PCR, we performed RT-PCR with different cycle numbers, then quantitated the amplification after blotting the amplified bands and hybridizing with a radioactive probe. We observed again a significant expression of Xebf3 in the caps treated with dexamethasone, both in the presence and absence of protein synthesis (data not shown). We also tested whether Xebf2 could directly activate Xebf3 in animal caps. By using a similar hormone-inducible fusion construct, Xebf2-hGR (O.P. and G.G.C., unpublished), we observed that Xebf2 activated Xebf3 in animal caps, but that this activation was eliminated when protein synthesis was blocked with cycloheximide, demonstrating that the regulation was indirect (data not shown). These results demonstrate that Xebf3 acts downstream of XNeuroD during neuronal differentiation in Xenopus and that in vitro hGR-XNeuroD activates Xebf3 directly in the absence of protein synthesis.
Delta/Notch-Mediated Lateral Inhibition Does Not Block the Function of Xebf3
In both invertebrates and vertebrates, the cascade of HLH transcription factors regulating neurogenesis is strictly regulated by Delta/Notch-mediated lateral inhibition. This cell-cell interaction mechanism is important for selecting the cells that will take on the neural fate, and prevents surrounding cells from becoming neurons (ArtavanisTsakonas et al., 1995; Lewis, 1996) . It has been shown that the function as well as the expression of X-ngnr-1 is sensitive to lateral inhibition and overexpression of X-ngnr-1 promotes ectopic neurogenesis in a scattered pattern due to the action of the lateral inhibition pathway . Xebf2/Xcoe2, which is activated by X-ngnr-1, controls the transition between neural competence and irreversible commitment, and, at the same time, promotes neuronal differentiation . Xebf2/Xcoe2 also promotes neurogenesis in a scattered pattern when overexpressed, and coinjection of Xebf2/ Xcoe2 with X-Dl1 stu causes an increase in the density of ectopic neurons induced by Xebf2/Xcoe2, suggesting that the ability of Xebf2/Xcoe2 to promote neurogenesis is sensitive to lateral inhibition . It has been shown that both X-ngnr-1 and Xebf2/Xcoe2 are able to activate expression of XNeuroD, a regulator of neuronal differentiation Dubois et al., 1998) . Embryos coinjected with both XNeuroD and Notch-ICD RNA, a constitutively active form of Notch, show the same distribution of ectopic neurons as those injected with XNeuroD alone (Chitnis and Kintner, 1996) . This result suggests that the ability of XNeuroD to promote neurogenesis is resistant to lateral inhibition and is probably modulated by other regulatory mechanisms, even though XNeuroD itself is able to induce X-Delta-1 and activate lateral inhibition (Chitnis and Kintner, 1996) .
If Xebf3 is functioning downstream of XNeuroD, then the activity of Xebf3 should similarly be insensitive to lateral inhibition. We therefore tested whether the activity of Xebf3 could be inhibited by coexpression with activated Notch. Two-cell stage embryos were injected with Xebf3 RNA (500 pg), Notch-ICD RNA (100 pg), or a combination of both and assayed by in situ hybridization at neural plate stages for expression of the neural markers N-tubulin and XNF-M. The embryos injected with Notch-ICD showed the expected block in primary neurogenesis (N-tubulin, 76%, n ϭ 17; and had no effect on XNF-M expression (Fig 7C) 100%, n ϭ 15; Fig. 7D ), while embryos injected with Xebf3 alone produced ectopic scattered neurons both in the neural plate and epidermis (Figs. 4C and 4D ). Embryos injected with both Notch-ICD and Xebf3 RNA and assayed by in situ hybridization for N-tubulin and XNF-M gave the same pattern of ectopic neurons as those injected with Xebf3 alone (N-tubulin, 66%, n ϭ 29; XNF-M, 86%, n ϭ 30; Figs. 7E and 7F) , showing that Xebf3 is resistant to lateral inhibition. We also coinjected some embryos with Notch-ICD and Xebf2/Xcoe2 RNA (500 pg) and observed a complete inhibition of neurogenesis in the majority of embryos (N-tubulin, 77%, n ϭ 27; XNF-M, 83%, n ϭ 35; Figs. 7G and  7H ). In the remainder of the cases, we found a very weak ectopic expression of both N-tubulin and XNF-M that was much more restricted than that observed in the embryos injected with Xebf2/Xcoe2 alone (data not shown). We did not see any difference in potency by injecting different amounts of RNA (Xebf3 300 pg, Xebf2/Xcoe2 800 pg; data not shown), confirming that Xebf2/Xcoe2 function is sensitive to lateral inhibition, while Xebf3 function is not. Because we show that both Xebf3 and XNeuroD are resistant to lateral inhibition, but Xebf3 induces a scattered pattern of ectopic neurons, it is possible that Xebf3 is modulated by other regulatory factors that may act during the late stages of neuronal differentiation.
In almost all of the embryos injected with XNeuroD and assayed by in situ hybridization, we noticed a downregulation of Xebf2/Xcoe2 expression ( Fig. 5B; 77% , n ϭ 26). To test whether this downregulation is due to the ectopic activation of lateral inhibition induced by exogenous XNeuroD, we coinjected two-cell stage embryos with the dominant negative form of Delta, X-Dl stu , either alone or in combination with XNeuroD. Overexpression of X-Dl1 stu caused an increase in Xebf2/Xcoe2 expression within the three stripes of primary neurons ( Fig. 7L; 94% , n ϭ 18), while Xebf3 expression was not influenced ( Fig. 7I; 100% , n ϭ 20). The block of lateral inhibition in XNeuroDoverexpressing embryos promoted ectopic activation of Xebf2/Xcoe2 both in the neural plate and epidermis ( Fig.  7N ; 92%, n ϭ 24), while the level of Xebf3 ectopic expression was not affected, compared to the embryos injected with XNeuroD alone (Figs. 5A and 7M; 76%, n ϭ 25). Therefore, the expression of Xebf2/Xcoe2, but not Xebf3, is sensitive to inhibition by Notch ensuring that in vivo Xebf3, but not Xebf2/Xcoe2, is activated by XNeuroD. This result might also explain our observation that Xebf2/Xcoe2 is weakly activated in caps isolated from XNeuroD-injected
FIG. 7.
Xebf3 is insensitive to Delta/Notch-mediated lateral inhibition mechanism. Embryos were injected with RNA at the two-cell stage then collected at neural plate stages and assayed by in situ hybridization for expression of the neural markers N-tubulin and XNF-M, and of Xebf3 and Xebf2/Xcoe2, as indicated at the top. Injected embryos are oriented with their anterior side down (dorsal view, injected side revealed by X-gal staining). Overexpression of an activated form of the Notch receptor (Notch-ICD) caused a suppression of N-tubulin expression (C) and no change in XNF-M expression (D) on the injected side. XNF-M is normally turned on at stage 19. Embryos coinjected with Notch-ICD and Xebf3 (E, F) gave a similar pattern of ectopic N-tubulin and XNF-M expression as with Xebf3 alone (see Figs. 4C and 4D) , suggesting that Xebf3 function was not inhibited by activated Notch. In contrast, embryos coinjected with Notch-ICD and Xebf2/Xcoe2 showed an inhibition of neurogenesis (G, H), as compared with embryos injected with Xebf2/Xcoe2 alone (Figs. 4E and 4F) . The block of the Delta/Notch pathway induced by injecting X-Dl1 stu did not influence Xebf3 expression (I) but caused an increase in the Xebf2/Xcoe2-positive neurons within the three stripes of primary neurons (L). When lateral inhibition was similarly blocked in XneuroD-injected embryos, overexpression of XNeuroD promoted ectopic expression of both Xebf3 and Xebf2/Xcoe2 (M, N). embryos (Fig. 5I) . It is possible that activation of the lateral inhibition pathway in isolated ectodermal explants is not as robust as in vivo or that mosaic inheritance of XNeuroD sets up a nonuniform lateral inhibitory mechanism where previously there was none, resulting in detectable activation of Xebf2/Xcoe2 in XNeuroD-injected caps. Our findings show that the sequential expression of these HLH proteins, in combination with the action of the lateral inhibition pathway, ensure that the molecular cascade that regulates primary neurogenesis in Xenopus is unidirectional, and that Xebf3 functions downstream of XNeuroD.
DISCUSSION
Xebf3 Is Structurally and Functionally Related to Other Members of the Ebf/Olf-1 Family
In Xenopus laevis, primary neurogenesis is controlled by a unidirectional cascade of HLH transcription factors that regulate neural determination and differentiation. In the last few years, multiple proteins in this pathway have been identified and analyzed on the basis of their activities and mutual interactions (Kageyama and Nakanishi, 1997; Lee, 1997) . In the present paper, we describe the cloning of Xebf3, a new member of the Ebf/Olf-1 family of HLH transcription factors, and analyze its role in this regulatory cascade. Xebf3 is most closely related to mouse Ebf3, a gene expressed in late differentiating neurons in the mantle layer of the developing neural tube (Garel et al., 1997) . Pairwise sequence comparisons indicate that Xebf3 is also closely related to Ebf2 (Garel et al., 1997; Malgaretti et al., 1997; Wang et al., 1997) and to its X. laevis ortholog, Xebf2/Xcoe2 , as well as to mouse Ebf1 , another gene expressed in differentiating neurons, for which no amphibian ortholog has been found to date. In vitro, XEBF3, like XEBF2/XCOE2, binds the recognition sequence of rat OLF-1, an imperfect palindromic sequence found in several olfactory gene promoters (Kudrycky et al., 1993) . The same recognition sequence is bound by all three murine Ebf genes (Wang et al., 1997) . Likewise, we demonstrate with luciferase reporter assays that XEBF3, like XEBF2/XCOE2, is a transcriptional activator. Therefore, XEBF3 shares several important biochemical properties with other members of the EBF family of transcription factors.
Xebf3 Functions as a Regulator of Neuronal Differentiation
In the developing Xenopus embryo, Xebf3 is expressed in differentiating primary neurons of the neural tube as well as in other parts of the developing nervous system. Xebf3 expression is detected in the three stripes of primary neurons at stage 15.5, which is after the onset of XNeuroD (Lee et al., 1995) , suggesting a putative role for Xebf3 in regulating late steps of neuronal differentiation. In Xenopus embryos, overexpression of Xebf3 leads to ectopic expression of the neuronal markers N-CAM, N-tubulin, and neurofilament-M, demonstrating the ability of Xebf3 to promote neuronal differentiation.
In animal caps cut from Xebf3-injected embryos, the same neuronal markers are activated, confirming the ability of Xebf3 to convert ectodermal cells into neurons. The lack of activation of the mesodermal marker muscle actin indicates that the neuralizing effect of Xebf3 is direct and independent of mesodermal signals. Therefore, Xebf3 shares one fundamental property with bHLH factors such as X-ngnr-1 and XNeuroD, namely the ability to promote ectopic neurogenesis when overexpressed, and the ability to   FIG. 8 . Model describing the transcriptional interactions of the molecular cascade that controls primary neurogenesis during Xenopus development, modified from Dubois et al. (1998) . The components of the original model from Dubois et al. (1998) directly neuralize animal cap tissue (Lee et al., 1995; . However, Ebf genes are structurally unrelated to these proneural bHLH transcription factors and the onset of Xebf3 expression during Xenopus primary neurogenesis suggests that it plays its primary role at a step subsequent to that of the bHLH genes. Furthermore, XNeuroD is still able to promote ectopic N-tubulin activation when coinjected with a dominant negative form of Xebf3 lacking the DNA binding domain (data not shown), confirming that Xebf3 is not required for early steps of neurogenesis. The overexpression of this Xebf3 dominant negative construct does cause a reduction of the endogenous expression of XNF-M (data not shown), so it is possible that Xebf3 is instead required for later steps in neuronal differentiation. Similarly, in mouse, all of the Ebf genes are activated in postmitotic layers of the embryonic neural tube (Garel et al., 1997; Malgaretti et al., 1997) , and likely control neuronal differentiation, rather than regulating the onset of neurogenesis.
Outside of the neural plate, Xebf3 is expressed at high levels in developing sensory tissues (trigeminal, otic and olfactory placodes, cranial neural crest) and, at the tailbud stage, in the dorsal neural tube. In addition, we find that Xebf3 overexpression ectopically activates XHox11L2 expression, a late marker of cranial and Rohon-Beard neurons, but does not induce motor neuron or interneuron markers. This evidence suggests that Xebf3 overexpression is sufficient to promote differentiation of sensory neurons in vivo, while not ruling out a possible contribution of this gene to the establishment or maturation of other neural lineages. It has been shown that the bHLH factor X-ngnr-1 controls neural determination during primary neurogenesis and subsequently contributes to the specification of sensory identity (Fode et al., 1998; Olson et al., 1998; Perron et al., 1999) . Likewise, our data suggest that Xebf3 might regulate some aspects of sensory neuron differentiation, likely at a later step in this cascade.
How is Xebf3 regulating neuronal differentiation? Since Xebf3 is a transcriptional activator it might directly regulate the expression of late neuronal differentiation genes. Overexpression of Xebf3 by RNA injection induces a strong and widespread expression of the neuronal differentiation marker XNF-M throughout the ectoderm on the injected side. The ectopic expression is detected prior to the onset of normal XNF-M expression in the embryo. In mouse, the NF-M promoter contains potential EBF/OLF-1 binding sites (A.B. and G.G.C., unpublished results), suggesting that in Xenopus there may be a direct activation of XNF-M by Xebf3. In addition, in rat and mouse olfactory epithelium, EBF1/OLF-1 can directly regulate the transcription of multiple olfactory-specific genes, such as G(olf), OMP (Olfactory Marker Protein), and olfactory receptor genes, that directly contribute to the differentiated phenotype of olfactory receptor neurons (Kudrycky et al., 1993; .
In addition, more indirect mechanisms may contribute to the regulation of neuronal differentiation by Xebf3. A 30-zinc finger DNA binding protein named ROAZ was identified as a physical interactor and transcriptional cofactor of EBF/OLF-1 in rat olfactory neurons . ROAZ interacts with all three murine members of the EBF family in vitro (Tsai and Reed, 1998) . Recently, it has been shown that ROAZ cooperates with SMAD proteins, which are important for transducing BMP2/4 signaling into the nucleus (Hata et al., 2000) . In Xenopus, XOAZ binds SMAD proteins involved in BMP2/4 signaling and may be a bifunctional partner of both SMAD and XEBF proteins. The Xoaz transcript is ubiquitous in the developing embryo until late neural plate stages, after which it becomes restricted to the anterior neural tube. When overexpressed, the XEBF proteins may compete with SMAD proteins for association with the common cofactor XOAZ and may thus antagonize BMP signaling at the intracellular level. Such an antagonistic interaction between the Ebf and BMP networks could play a crucial role later in nervous system development since BMP signaling affects neural cell-type specification and differentiation (Liem et al., 1997; LaBonne and Bronner-Fraser, 1998; Alder et al., 1999; Barth et al., 1999; Nguyen et al., 2000) . For example, BMPs have been shown to inhibit neurogenesis in cultures from olfactory epithelium (Shou et al., 1999) and to affect the differentiation of neural stem cells in the adult CNS (Lim et al., 2000) . However, antagonism of BMP signaling alone is extremely unlikely to account for the specific ability of Xebf3 to promote XNF-M gene expression and sensory neuron differentiation. Further studies are required in order to test whether this mechanism plays a role in the ability of Xebf3 to promote neurogenesis.
Xebf3 Functions Downstream of XNeuroD
Our results show that Xebf3 functions downstream of XNeuroD and that the hormone-inducible form of XNeuroD (hGR-XNeuroD) directly activates the expression of Xebf3 in vitro. In addition, overexpression of X-ngnr-1, Xebf2/Xcoe2, or XNeuroD is able to activate Xebf3 expression, but not vice versa, confirming that the regulatory cascade of HLH transcription factors that controls primary neurogenesis in Xenopus is unidirectional. In particular, activation of the lateral inhibition pathway by XNeuroD ensures that Xebf3, but not Xebf2, is normally activated in vivo downstream of XNeuroD. Based on our results, we propose a model in which Xebf3 is turned on after the sequential activation of X-ngnr-1, Xebf2/Xcoe2, and XNeuroD (Fig. 8) . However, the robust ectopic activation of Xebf2/Xcoe2 as a result of XNeuroD overexpression and inhibition of Notch signaling raises questions on the relative position of Xebf2/Xcoe2 within the neurogenetic cascade. In fact, Xebf2/Xcoe2 might lie downstream of XNeuroD in that pathway and the activation of XNeuroD by Xebf2/Xcoe2 may possibly stem from a positive feedback mechanism.
Xebf3 is likely not the exclusive factor functioning downstream of XNeuroD. When Xebf3 is overexpressed, we observe a more restricted pattern of ectopic neurons, mainly confined to the posterior part of the embryo, than that induced by overexpression of XNeuroD. It is possible that, in the same neurons, XNeuroD activates, directly or indirectly, multiple factors, including Xebf3, that interact to regulate neuronal differentiation. Another possibility is that Xebf3 functions downstream of XNeuroD only in some neurons, which are differentiating toward a particular phenotype. In support of the latter hypothesis, the expression patterns of Xebf3 and XNeuroD overlap only in some regions of the developing embryo and the overexpression of Xebf3 promotes ectopic activation of the sensory-specific gene XHox11L2.
Xebf3 and Xebf2/Xcoe2 Have Different Functions during Neurogenesis in Xenopus
In this paper, we demonstrate that XEBF3 and XEBF2/ XCOE2 show similar DNA binding and transactivation activity in vitro. Nevertheless, several lines of evidence support the idea that XEBF3 and XEBF2/XCOE2 have different functions in vivo. First, the two Xebf genes are turned on at different times in the developing embryo. Xebf2/Xcoe2 is activated earlier, at stage 12.5, in the three stripes of primary neurons, when the transition between neural competence and irreversible commitment occurs . In contrast, Xebf3 is activated later in the neural plate, at stage 15.5, while the primary neurons are differentiating. This is in agreement with observations made in the mouse neural tube, where Ebf2 is expressed in early postmitotic neurons of the subventricular zone, while Ebf1 and Ebf3 are expressed in more differentiated neurons of the mantle layer (Garel et al., 1997) . Second, Xebf2/ Xcoe2 functions downstream of X-ngnr-1 , while our results show that Xebf3 acts downstream of XNeuroD. The above differences likely reflect the existence of distinct cis-acting regulatory sequences, driving expression of the two genes at different times and under control of different factors in the genetic cascade regulating neurogenesis.
Our results strongly indicate that additional differences between Xebf3 and Xebf2/Xcoe2 exist, and that the two genes, although closely related, encode proteins endowed with intrinsically distinct functional properties. For example, overexpression of Xebf2/Xcoe2 activates expression of XNeuroD , while Xebf3 does not, consistent with their roles at different steps of primary neurogenesis. In addition, the ability of Xebf2/Xcoe2 to promote the formation of ectopic neurons is sensitive to inhibition by activated Notch, while Xebf3 function in this assay is insensitive to inhibition. This suggests that Xebf2/ Xcoe2, unlike Xebf3, is inhibited by Notch activation in the same cell, besides possibly triggering lateral inhibition in neighboring ones, and that Xebf2/Xcoe2 is not only inhibited at the transcriptional level, but also posttranscriptionally. One hypothesis is that Xebf2/Xcoe2 function may be repressed by a Notch-activated cofactor that interacts with XEBF2/XCOE2 but not with XEBF3. The differential interaction of Xebf3 and Xebf2/Xcoe2 with the Notch signaling pathway might translate into distinct functional properties of the Ebf genes during early and late differentiation.
The mechanisms underlying the key functional differences observed between Xebf3 and Xebf2/Xcoe2 are not clear. A comparison of XEBF3 and XEBF2/XCOE2 protein sequences reveals that the greatest discrepancies between the two closely related proteins reside in the putative protein-protein interaction domain, located in the C-terminal region of EBF proteins . It is therefore possible that XEBF3 and XEBF2/XCOE2 interact with different cofactors that confer distinct functional properties upon these proteins. In contrast, the highest degree of similarity is found in the DNA binding domain, in keeping with our gel mobility shift data.
In conclusion, we have cloned and characterized Xebf3, a new member of the Ebf/Olf-1 transcription factors family. Our work clarifies the unique role of Xebf3 downstream of XNeuroD as a regulator of neuronal differentiation during primary neurogenesis in Xenopus. In addition, these results demonstrate that the two Xenopus members of this family, Xebf3 and Xebf2/Xcoe2, have distinct functions and that they interact with different components of the pathway regulating neuronal differentiation. The emerging properties of the Ebf genes should warrant their recognition as key regulators of vertebrate neural development.
